Last update 20 Mar 2025

Anti-BCMA CAR-T(Institute of Hematology & Blood Diseases Hospital)

Overview

Basic Info

Drug Type
CAR-T
Synonyms
CART-ASCT-CART2
Target
BCMA
Action
inhibitors
Mechanism
BCMA inhibitors(B-cell maturation protein inhibitors), Immunologic cytotoxicity, T lymphocyte replacements
Therapeutic Areas
NeoplasmsImmune System DiseasesCardiovascular Diseases+ [2]
Active Indication
Residual NeoplasmPlasma Cell Leukemia
Inactive Indication-
Originator Organization
Hematology Hospital of Chinese Academy of Medical Sciences
Active Organization
Hematology Hospital of Chinese Academy of Medical Sciences
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

7
Clinical Trials associated with Anti-BCMA CAR-T(Institute of Hematology & Blood Diseases Hospital)
NCT06880393
/ RecruitingPhase 2IIT
A Study of BCMA CAR-T for Dynamic High-risk Patients With Multiple Myeloma
NCT06793449
/ RecruitingPhase 2IIT
A Prospective, Non-inferiority Study Comparing VRD±D Followed by BCMA CAR-T Cell Therapy Versus VRD±D Followed by Autologous Hematopoietic Stem Cell Transplantation in Transplant-eligible Patients With Newly-diagnosed Multiple Myeloma
NCT05979363
/ RecruitingPhase 2IIT
Safety and Efficiency of VRd Combining BCMA CAR-T Regimen for Transplant-ineligible Patients With Primary Plasma Cell Leukemia: a Prospective, Single-arm, Single-center, Phase II Study.
100 Clinical Results associated with Anti-BCMA CAR-T(Institute of Hematology & Blood Diseases Hospital)
Login to view more data
100 Translational Medicine associated with Anti-BCMA CAR-T(Institute of Hematology & Blood Diseases Hospital)
Login to view more data
100 Patents (Medical) associated with Anti-BCMA CAR-T(Institute of Hematology & Blood Diseases Hospital)
Login to view more data
100 Deals associated with Anti-BCMA CAR-T(Institute of Hematology & Blood Diseases Hospital)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Residual NeoplasmPhase 2
China
Hematology Hospital of Chinese Academy of Medical Sciences
29 May 2023
Plasma Cell LeukemiaPhase 2
China
Hematology Hospital of Chinese Academy of Medical Sciences
25 Apr 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free